- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.06. | Affibody gets izokibep 'back on track' while seeking 'new home' after drug's Acelyrin rejection | ||
| 04.06. | Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2 | ||
| 04.06. | As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too | ||
| 04.06. | Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3 | ||
| 04.06. | From business strategy to CAR-T responses, for Cabaletta it's all about 'durability' | ||
| 04.06. | Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC | ||
| 04.06. | Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer | ||
| 03.06. | Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact | ||
| 02.06. | New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells | ||
| 02.06. | Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases | ||
| 02.06. | ASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push | ||
| 02.06. | Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks | ||
| 02.06. | Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial | ||
| 02.06. | Praxis pauses one of its seizure programs after phase 2 fail | ||
| 01.06. | At ASCO 2026, a 'paradigm shift' for a rare gut cancer looms | ||
| 01.06. | Agios signs $165M deal for blood disorder drug from Korea's Oscotec that flunked phase 2 study | ||
| 01.06. | Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo | ||
| 01.06. | Servier inks $2.6B buyout of Edgewise's muscular dystrophy unit to beef up neurology pipeline | ||
| 01.06. | Lilly locks in 5-program R&D pact with China's Haisco worth up to $3B, but targets unclear | ||
| 01.06. | Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome | ||
| 30.05. | In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach | ||
| 29.05. | Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform | ||
| 29.05. | AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval | ||
| 29.05. | Agios' next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed | ||
| 29.05. | Boston, China and the future of biotech |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.